A Genome-wide siRNA Screen for the Identification of Cisplatin Resistance Mechanisms in CancerTuesday, 4 September 2012 at 11:45  Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.comPatients with non-small cell lung cancer (NSCLC) are routinely treated with cytotoxic agents such as cisplatin. To identify novel factors involved in the cellular response to cisplatin, we transfected human NSCLC A549 cells with a panel of small interfering RNAs covering the entire genome (two siRNAs targeting a total of 23,078 gene products) and then explored the effects of the transfection on cisplatin-mediated cytotoxicity and reduction in cell numbers by measuring the release of lactate dehydrogenase (LDH) into the cell supernatant and the conversion of a tetrazolium salt (WST1, respectively. |
Add to Calendar ▼2012-09-04 00:00:002012-09-05 00:00:00Europe/LondonGenomics Research EuropeGenomics Research Europe in Frankfurt, GermanyFrankfurt, GermanySELECTBIOenquiries@selectbiosciences.com
